Alpha Tau Medical (DRTS) Cash from Investing Activities (2021 - 2022)

Alpha Tau Medical (DRTS) posted quarterly Cash from Investing Activities of -$92.4 million for Q2 2022, down 30898.99% on a QoQ basis from -$298000.0 in Q1 2022.

Alpha Tau Medical (DRTS) Cash from Investing Activities (2021 - 2022) Analysis & Trends

Alpha Tau Medical (DRTS) has reported Cash from Investing Activities for 2 consecutive years, with -$92.4 million the latest figure, recorded in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,045.06 Bn 1,045.06 Bn - -
4 BeOne Medicines 470.64 Bn 465.84 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 122.91 Bn 115.67 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.77 Bn 62.77 Bn - -
8 Argenx Se 56.21 Bn 51.02 Bn 1.41 Bn -
9 Revolution Medicines 37.60 Bn 37.60 Bn - 172.62 Mn
10 Alpha Tau Medical 1.11 Bn 1.11 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 -92.38 Mn
Jun 30, 2022 -92.38 Mn
Mar 31, 2022 -298,000.00
Mar 31, 2022 -298,000.00
Mar 31, 2021 -609,000.00
Mar 31, 2021 -609,000.00